Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal Pharmaceuticals LLC today announced the launch of generic Esomeprazole strontium delayed-release capsules 49.3 mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium. It contains the same active moiety (esomeprazole) in a different salt form as found in the leading PPI brand Nexium (esomeprazole magnesium) and presents a potentially more affordable treatment option for GERD in adult patients.

6 Jan 2014

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

Combination of medication and psychological therapy effective for treating chronic migraines in children

Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American Medical Association by Mark Connelly, PhD, a pain psychologist and co-director of the Comprehensive Headache Clinic at Children's Mercy Hospital.

26 Dec 2013

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing in the December 25 issue of JAMA.

25 Dec 2013

Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

Breast cancer patients experience fewer side effects while being treated with a widely used drug called an aromatase inhibitor when they get acupuncture - either the real treatment or a "sham" procedure, according to a new study led by researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

23 Dec 2013

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.

21 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Anesthesiology residents want frequent feedback on clinical performance

Anesthesiology residents want frequent feedback on their clinical performance, as well as evaluations of their performance compared to their fellow residents as a whole, according to a study in the January issue of Anesthesiology.

19 Dec 2013

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease.

17 Dec 2013

Pregnant women, infants should avoid unpasteurized milk products, urge pediatricians

Pregnant women, infants and young children should avoid raw or unpasteurized milk and milk products and only consume pasteurized products, according to a new policy statement from the American Academy of Pediatrics.

16 Dec 2013

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Arthur L. Day, M.D., professor of neurosurgery at The University of Texas Health Science Center at Houston and a neurosurgeon at the Mischer Neuroscience Institute at Memorial Hermann-Texas Medical Center, has received one of the top honors awarded by the Congress of Neurological Surgeons.

14 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Researchers develop first test to identify acute mountain sickness

The first test to identify acute mountain sickness has been developed by a team of researchers in Italy and France and is presented today at EuroEcho-Imaging 2013. The test could revolutionise trekking and climbing by predicting who will develop the potentially deadly condition so they can avoid high altitudes, ascend more gradually or take preventative medication.

12 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

Nausea News and Research

Further Reading

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Combination of medication and psychological therapy effective for treating chronic migraines in children

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Anesthesiology residents want frequent feedback on clinical performance

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Pregnant women, infants should avoid unpasteurized milk products, urge pediatricians

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Researchers develop first test to identify acute mountain sickness

Crealta to acquire all assets of Savient Pharmaceuticals

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News